Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

Modugula, Harika; Kumar, Anoop

doi:10.2174/1871527319666200303120147

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postmarketing studies have indicated an increase in the frequency of existing ADRs and the emergence of unknown ADRs. The unknown ADRs were observed due to limitations of clinical trials such as limited population, controlled environment, duration, etc [ 21 , 22 ]. The ADRs which were observed from post-marketing studies are complied in Table ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

Risks Associated with Vortioxetine in the Established Therapeutic Indication

Verma

Kumar

2021

Self Cite

View full text Add to dashboard Cite

Background: Vortioxetine is approved for the treatment of Major Depressive Disorder (MDD). However, the safety of this drug in a large group of populations is still unclear. Thus, we have tried to analyze the risk profile of vortioxetine. Material and Methods: The data related to the risk profile of vortioxetine has been extracted from Pub-Med from January 2014 to May 2019. The adverse drug reactions (ADRs) have been categorized into a listed and unlisted categories as per Summary of product characteristics (SmPC) of the innovator. Further, unlisted ADRs have been analyzed as per Naranjo Scale. Results: The galactorrhea, hyperprolactinemia, glycolimia, exacerbation of anxiety, weight gain, edema, excessive itching, petechiae, and ecchymoses have been observed with the use of vortioxetine and falls under the unlisted category. Further, the causality assessment results have shown probable relation between vortioxetine and galactorrhea, hyperprolactinemia, edema, excessive itching, ecchymoses, and petechiae. The weight gain, glycolimia and exacerbation of anxiety have a possible relationship with vortioxetine. The common ADRs observed with the use of vortioxetine are nausea, diarrhea, constipation, vomiting, pruritus including pruritus generalized, abnormal dreams, and dizziness. Conclusion: In conclusion, more data is required to establish the strong relationship between vortioxetine and reported unlisted ADRs.

show abstract

Section: Discussionmentioning

confidence: 99%

Risks Associated with Vortioxetine in the Established Therapeutic Indication

Verma

Kumar

2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the case of hypersexuality, although without strong scientific evidence, an iatrogenic association between antipsychotic drugs and hypersexuality has been found [62]. This association has been observed also in young adults diagnosed with first-episode psychosis (FEP), [61].…”

Section: Evidencementioning

confidence: 99%

Hypersexuality as a tip of the iceberg of a primary psychopathology: a joined position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) and of the Italian Society of Psychopathology (SOPSI)

Limoncin

Ciocca

Castellini

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

In the last years, hypersexual behavior has been broadly scientifically studied. The interest in this topic, belonging to psycho-sexology and sexual medicine, has been due to its still unclear aetiology, nature, and its manifestation in relationship with several organic and psychopathological conditions. So, the specialist (the psychologist, psychiatrist, endocrinologist, neurologist) may encounter some difficulties in diagnosing and managing this symptom. The first main objective of this position statement, which has been developed in collaboration between the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Psychopathology (SOPSI) is to give to the reader evidence about the necessity to consider hypersexuality as a symptom related to another underlying condition. Following this consideration, the second main objective is to give specific statements, for the biopsychosocial assessment and the diagnosis of hypersexual behavior, developed on the basis of the most recent literature evidence. To develop a psycho-pharmacological treatment tailored on patients' needs, our suggestion is to assess the presence of specific comorbid psychopathological and organic conditions, and the impact of pharmacological treatments on the presence of an excess of sexual behavior. Finally, a suggestion of a standardized psychometric evaluation of hypersexuality will be given.

show abstract

Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia

Rathore

Asati

Mishra

et al. 2022

In Silico Pharmacol.

View full text Add to dashboard Cite

Piperidine and piperazine derivatives exhibit a diverse range of biological applications, including antipsychotic activity. In this study, a dataset of molecules containing piperidine, piperazine moieties that possess serotonin 5-HT 2A and dopamine D 2 inhibitory activity have been chosen for Pharmacophore modeling, Quantitative Structure–Activity (3D-QSAR) Relationship, Molecular docking, and ADME studies. The pharmacophoric hypothesis was found to be AAHPRRR_1 having seven features as one H-bond acceptor (A), one hydrophobic (H), one positive ion acceptor (P), and three aromatic rings (R), with survival score = 6.465 and AUC = 0.92. Based on the best hypothesis, the ZINC-Data base was virtually screened to find out the lead molecules. 3D-QSAR model, including internal and external validation showed comparative molecular field analysis (CoMFA) against 5HT 2A ( q 2 = 0.552, R 2 = 0.889, and r 2 poured. = 0.653 and number of component 5) and comparative molecular similarity indices analysis (CoMSIA) ( q 2 = 0.599, R 2 = 0.893, and r 2 pred. = 0.617), for D 2 (CoMFA, q 2 = 0.577, R 2 = 0.863, and r 2 pred. = 0.598) (CoMSIA, q 2 = 0.532, R 2 = 0.82) all results exhibited better productivity and significant statistical reliability of the model. The docking study was carried out on the crystal structure of 5-HT 2A having PDB ID; 6A93 and D 2 receptor having PDB ID; 6CM4. The screened compound ZINC74289318 possess a higher docking score − 10.744 and − 11.388 than co-crystallized ligand docking score − 8.840 and − 10.06 against 5-HT 2A and D 2 receptor respectively. Further, ZINC74289318 was screened for all drug-likeness parameters and no showed violation of the Lipinski rule of five. Also, it was found to possess good bioavailability of 0.55 with synthetic accessibility of 4.42 which is greater than risperidone.

show abstract

Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

Cited by 3 publications

References 31 publications

Risks Associated with Vortioxetine in the Established Therapeutic Indication

Risks Associated with Vortioxetine in the Established Therapeutic Indication

Hypersexuality as a tip of the iceberg of a primary psychopathology: a joined position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) and of the Italian Society of Psychopathology (SOPSI)

Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia

Contact Info

Product

Resources

About